EVALUATION OF CLINICAL FEATURES, LABORATORY FINDINGS, AND TREATMENT OF SOME BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AT NGHE AN FRIENDSHIP GENERAL HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the initial treatment outcomes and some factors related to the treatment outcomes of essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). Subjects and Methods: A non-controlled clinical intervention was conducted on 49 patients who were newly diagnosed with ET, PV, or PMF between January 2023 and June 2024 at Nghe An Friendship General Hospital. The patients who met the research criteria were diagnosed according to the Ministry of Health's diagnostic guidelines and the 2008 WHO diagnostic criteria. All 49 patients were treated based on the 2022 "Guidelines for the Diagnosis and Treatment of Some Hematologic Diseases". The research team assessed treatment effectiveness upon hospital discharge and after three months of treatment. Results: The average age of the study group was 65.51 ± 12.7 years; the male-to-female ratio was 1.3/1. PMF patients had a higher average age (75.67 ± 12.78 years) compared to those with ET and PV. Microcirculatory disorder symptoms were more common in the PV and ET groups, at 84% and 38.9%, respectively. Arterial thrombosis (such as cerebral infarction and myocardial infarction) was primarily found in the ET and PV groups, accounting for 33.3% and 24%, respectively. Splenomegaly was present in all three disease groups, with PMF patients predominantly having grade III and IV splenomegaly. The JAK2V617F mutation rate in the PMF, PV, and ET groups was 100%, 92%, and 83.3%, respectively. Both ET and PV groups had 100% response to induction therapy. After three months, the average platelet count (PLT) in the ET group was 499 G/l, while the PV group had an average hemoglobin (Hgb) level of 149 g/l after three months of treatment. Conclusion: Treatment for PV and ET showed hematological response during induction therapy, with gradual stabilization after three months. In contrast, the treatment effectiveness for the PMF group remains low, with 100% of patients still dependent on blood transfusions.
Article Details
Keywords
Polycythemia vera, Essential thrombocythemia, Primary myelofibrosis, JAK2V617F.
References
2. Chen M., Zhang C., Hu Z. và cộng sự. (2021). CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms. Biosensors (Basel), 11(8), 247.
3. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7): 1703-1719. doi:10.1038/ s41375-022-01613-1
4. van Genderen PJ, Prins FJ, Michiels JJ, Schrör K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999;104(3): 438-441. doi:10.1046/ j.1365-2141.1999.01224.x
5. Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014; 124(19): 3021-3023. doi:10.1182/blood-2014-07-591610
6. Yap YY, Law KB, Sathar J, et al. The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Exp Hematol Oncol. 2018;7:31.
7. Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94(4):599-610.
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet Lond Engl. 2005;365(9464): 1054-1061. doi:10.1016/ S0140-6736(05)71142-9